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Intratumour heterogeneity fuels carcinogenesis and allows circumventing
specific targeted therapies. HER2 gene amplification is associated with poor
outcome in invasive breast cancer. Heterogeneous HER2 amplification has
been described in 5–41% of breast cancers. Here, we investigated the genetic
differences between HER2-positive and HER2-negative admixed breast can-
cer components. We performed an in-depth analysis to explore the potential
heterogeneity in the somatic mutational landscape of each individual tumour
component. Formalin-fixed, paraffin-embedded breast cancer tissue of ten
patients with at least one HER2-negative and at least one HER2-positive
component was microdissected. Targeted next-generation sequencing was
performed using a customized 53-gene panel. Somatic mutations and copy
number variations were analysed. Overall, the tumours showed a heteroge-
neous distribution of 12 deletions, 9 insertions, 32 missense variants and 7
nonsense variants in 26 different genes, which are (likely) pathogenic. Three
splice site alterations were identified. One patient had an EGFR copy num-
ber gain restricted to a HER2-negative in situ component, resulting in
EGFR protein overexpression. Two patients had FGFR1 copy number gains
in at least one tumour component. Two patients had an 8q24 gain in at least
one tumour component, resulting in a copy number increase in MYC and
PVT1. One patient had a CCND1 copy number gain restricted to a HER2-
negative tumour component. No common alternative drivers were identified
in the HER2-negative tumour components. This series of 10 breast cancers
with heterogeneous HER2 gene amplification illustrates that HER2 positivity
is not an unconditional prerequisite for the maintenance of tumour growth.
Many other molecular aberrations are likely to act as alternative or collabo-
rative drivers. This study demonstrates that breast carcinogenesis is a
dynamically evolving process characterized by a versatile somatic mutational
profile, of which some genetic aberrations will be crucial for cancer progres-
sion, and others will be mere ‘passenger’ molecular anomalies.
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ASCO/CAP, American Society of Clinical Oncology/College of American Pathologists; CNV, copy number variation; DCIS, ductal carcinoma
in situ; ER, oestrogen receptor; FEDERA, Federation of Dutch Medical Scientific Societies; FFPE, formalin-fixed, paraffin-embedded; ILC,
invasive lobular carcinoma; LCIS, lobular carcinoma in situ; lncRNA, long noncoding RNA; NGS, next-generation sequencing; NST, no special
type; PR, progesterone receptor; SNP, single nucleotide polymorphism.
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1. Introduction
Cancer is a genetic disease, resulting from an accumu-
lation of successive somatic gene mutations that drive
cancer cell proliferation (Tomasetti et al., 2017). Inva-
sive breast cancer is heterogeneous and comprises dif-
ferent molecular subtypes (Perou et al., 2000). Around
12–20% of invasive breast cancers have a HER2 gene
amplification, which generally results in overexpression
of the HER2 protein (Kraus et al., 1987; Ross, 2010;
Venter et al., 1987). The HER2 gene, located at 17q12-
21, encodes a 185 kDa transmembrane tyrosine kinase
receptor. The HER2 receptor has no known ligand of
its own but activates other receptors of the HER fam-
ily by heterodimerization (Barros et al., 2010). HER2
amplification is associated with shorter disease-free
and overall survival in patients with node-negative and
node-positive invasive breast cancer treated with adju-
vant chemotherapy and/or local radiation (Slamon
et al., 1987, 1989). With the advent of the humanized
monoclonal anti-HER2 antibody trastuzumab (Her-
ceptin; Genentech, San Francisco, CA, USA), HER2
has evolved from a mere prognostic marker to a pre-
dictive marker and a target for therapy (Ross and
Fletcher, 1999). Since then, the anti-HER2 treatment
arsenal has substantially expanded, and current thera-
peutic options include trastuzumab, pertuzumab (Per-
jeta; Genentech), trastuzumab emtansine or T-DM1
(Kadcyla; Genentech) and lapatinib (Tykerb;
GlaxoSmithKline, Brentford, UK).
Most HER2-positive carcinomas, both in situ and
invasive, present with homogeneous HER2 overexpres-
sion and amplification, implying that it is a key molec-
ular event that propels cancer cell proliferation. Such
genetic events occur early in the process of carcinogen-
esis and are designated ‘truncal’ somatic events
(McGranahan et al., 2015). However, an intratumoral
heterogeneous pattern of HER2 amplification is not
uncommon. Heterogeneity has been described in 5–
41% of HER2-positive breast cancers, depending on
its definition (Cottu et al., 2008; Ng et al., 2015; Ohls-
chlegel et al., 2011). The latest ASCO/CAP guidelines
do not define intratumour heterogeneity (Wolff et al.,
2018), but previous studies discerned regional from
genetic heterogeneity (Bartlett et al., 2011; Hanna
et al., 2014; Seol et al., 2012; Vance et al., 2009).
Genetic HER2 heterogeneity is defined as > 5% and
< 50% of infiltrating tumour cells presenting with a
HER2 copy number ≥ 6 (Pekar et al., 2019; Vance
et al., 2009). Regional heterogeneity comprises an
amplified tumour component admixed with a negative
and/or equivocal tumour component based on
immunohistochemistry and ISH studies (Bartlett et al.,
2011; Cottu et al., 2008; Seol et al., 2012). The
observed heterogeneity suggests that in some tumours,
not all cancer cells are depending on the HER2 onco-
gene. Other genomic aberrations might act as potent
alternative drivers of cancer cell proliferation and inva-
sion in HER2-negative subclones, such as the previ-
ously identified BRF2 and DSN1 gene amplification
and the HER2 p.I767M somatic mutation (Ng et al.,
2015).
In the current study, we aimed to further explore
the landscape of somatic mutations and copy number
variations (CNVs) in HER2-heterogeneous breast can-
cers. We performed an in-depth analysis of ten breast
cancers containing at least two distinct components
with different HER2 expression and copy number pro-
files, designated regional HER2 heterogeneity. We
investigated whether these immunohistochemically dis-
tinct components were clonally related and whether
the HER2-negative components were associated with
specific molecular aberrations that might act as alter-
native drivers of carcinogenesis.
2. Materials and methods
2.1. Patient samples
This retrospective study collected formalin-fixed, paraf-
fin-embedded (FFPE) tissue samples from 10 breast
cancer patients who were treated between 2010 and
2018 at the Erasmus Medical Center Cancer Institute
(Rotterdam, the Netherlands). Coded leftover patient
material was used in accordance with the Code of
Conduct of the Federation of Medical Scientific Soci-
eties in the Netherlands (FEDERA, 2011), as previ-
ously described (Agahozo et al., 2019). The study
methodologies conformed to the standards set by the
Declaration of Helsinki. The study methodologies were
approved by the local ethics committee. Both core
biopsies and resection specimens were eligible. Any
histological type of breast cancer was included, pro-
vided that the tumour presented with regional hetero-
geneous HER2 amplification and corresponding
heterogeneous HER2 protein overexpression, as previ-
ously described (Seol et al., 2012). Heterogeneous
HER2 status was defined as the presence of at least
one HER2-positive in situ and/or invasive component
and at least one HER2-negative in situ and/or invasive
component, as demonstrated by immunohistochemical
and in situ hybridization (ISH) analysis. These differ-
ent components had to be in close proximity of one
another: all components were present in a single tissue
block (with the exception of axillary lymph node
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metastases, if present). One representative tissue block
was selected for all subsequent analyses.
2.2. Immunohistochemistry
Four-µm-thick FFPE tissue sections were mounted on
Superfrost plus slides (Menzel-Gl€aser, Braunschweig,
Germany). Immunohistochemical stainings for oestro-
gen receptor (ER), progesterone receptor (PR), the
myoepithelial cell marker p63, E-cadherin, HER2,
FGFR1 and EGFR were performed using an auto-
matic immunostainer (Benchmark XT; Ventana Medi-
cal Systems, Tucson, AZ, USA), according to the
manufacturer’s instructions (Table S1). HER2 expres-
sion was assessed according to the ASCO/CAP guideli-
nes (Wolff et al., 2018). ER expression and PR
expression were scored as percentages, regardless of
the intensity. Hormone receptor status was determined
according to the ASCO/CAP guidelines (Hammond
et al., 2010). Surrogate molecular intrinsic subtyping
was based on the combined ER/PR/HER2 status.
2.3. HER2 in situ hybridization analysis
Automated HER2 ISH analysis was performed on all
cases using the BenchMark ULTRA (Ventana Medical
Systems). Four-µm-thick FFPE tissue sections were
deparaffinized and incubated with cell conditioning 2
(CC2) buffer at 86 °C for 28 min. Tissue sections were
treated with ISH-Protease-3 at 36 °C for 12 min, fol-
lowed by HER2 probe denaturation at 96 °C for
8 min and hybridization at 80 °C for 6 min. UltraView
SISH was used for detection, and haematoxylin II was
used as counterstain. Tumour components were con-
sidered HER2-amplified when a mean HER2 copy
number of ≥ 6 per cell was observed, in accordance
with the ASCO/CAP guidelines (Wolff et al., 2018).
2.4. DNA extraction
All tissue sections were first reviewed by two breast
pathologists (MRVB and CHMVD) who selected
tumour areas with an estimated minimum tumour cell
percentage of 30%. Ten consecutive FFPE 5-µm-thick
tissue sections were deparaffinized and haematoxylin-
stained prior to microdissection. Selected tumour areas
and normal tissue areas were microdissected manually
into 5% Chelex 100 Resin (Bio-Rad, Hercules, CA,
USA) Cell lysis solution (Promega, Madison, WI,
USA), using a sterile scalpel. DNA was extracted by
proteinase K (Roche, Mannheim, Germany) digestion
by overnight incubation at 56 °C. Proteinase K was
inactivated at 95 °C for 10 min. Finally, the samples
were centrifuged for 5 min at 20 000 g to remove
remaining cell debris and Chelex resins. The DNA was
collected into new tubes and stored at 80 °C until
further use. DNA concentrations were measured by a
Qubit 2.0 fluorometer (Thermo Fisher Scientific, Wal-
tham, MA, USA).
2.5. Targeted next-generation sequencing
For targeted next-generation sequencing (NGS), a cus-
tom-made amplicon panel was applied. This panel
comprised 2778 amplicons covering 53 genes
(Table S2), including single nucleotide polymorphisms
(SNPs) and hotspot mutation regions. Gene selection
for this panel was based on two large tumour profiling
studies (ICGC/TCGA and METABRIC), as well as
frequently found driver mutations in breast cancer
(Koboldt et al., 2012; Nik-Zainal et al., 2016). The Ion
AmpliSeq Designer tool was used to design amplicons
for the multiplex PCR assay, thereby aiming for 150-
bp amplicons and allowing efficient amplification of
fragmented DNA isolated from FFPE tissue. Full
sequence coverage of large exons required amplifica-
tion and sequencing of overlapping amplicons. There-
fore, the multiplexed PCR was split into two reactions,
using 10 ng of DNA for each reaction. The Ion
AmpliSeq Library Kit Plus (Thermo Fisher Scientific)
protocol was used to process the samples analysed by
the Ion AmpliSeq custom 53-gene panel, according to
the manufacturer’s instructions. Each sample was bar-
coded using IonXpress barcode adapters, allowing
multiplexed sequencing. A total of 18 PCR cycles were
performed. Ten samples were multiplexed on an Ion
540 Chip and sequenced on the Ion S5XL Semicon-
ductor Sequencer (Thermo Fisher Scientific, Waltham,
MA, USA).
2.6. Mutation analysis
The VARIANT CALLER v5.6.0.4 (Thermo Fisher Scien-
tific) was used for variant calling. Filtering was per-
formed by the ‘somatic low stringency’ default of the
Torrent Variant Caller. Variants were annotated in a
local Galaxy pipeline (www.galaxyproject.org) using
ANNOVAR (Wang et al., 2010). Exonic and splice site
variations were selected for analysis. Synonymous
point mutations, as well as variants identified as com-
mon polymorphisms in the 1000 Genomes database
(with a frequency of > 1%), were removed from the
dataset. Variants were kept in the dataset if they had a
minimum read depth of 100 reads and if they were
present within a tumour component with a frequency
higher than 10%. Variants were excluded if a strand
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artefact was suspected (forward/reverse or reverse/for-
ward ratio of < 1/10). For each case, a patient-
matched normal tissue sample was analysed to verify
whether the identified variants were somatic or germ-
line. Pathogenic and likely pathogenic variants were
considered germline if their variant allele frequency
ranged within 45–55% in the normal tissue sample.
Four prediction algorithms, MUTATIONTASTER (http://
www.mutationtaster.org/), PROVEAN (http://provean.jc
vi.org/index.php), UMD-PREDICTOR (http://umd-predic
tor.eu/) and SIFT (https://sift.bii.a-star.edu.sg/), were
used to predict the effects of coding nonsynonymous
variants. The Catalogue of Somatic Mutations in Can-
cer (COSMIC; https://cancer.sanger.ac.uk/cosmic) was
interrogated to assess for previous reports on the
selected variants. Variants were selected when at least
three of the four prediction algorithms indicated that
the variant was pathogenic or probably pathogenic. If
this criterion was not met, the variant was retained
only if the COSMIC database indicated it was a
known pathogenic or likely pathogenic variant. All
variants were reported at the cDNA level (c. annota-
tion) and the protein level (p. annotation) according to
the Human Genome Variation Society (HGVS)
nomenclature (Richards et al., 2015).
2.7. Copy number variation analysis
The presence of high-level gene copy number gains
was investigated by using the relative coverage, as pre-
viously described (Eijkelenboom et al., 2019). Sample
normalization was performed to correct for differences
in the number of total reads. The normal tissue sam-
ples of all patients constituted the reference series. The
normalized coverage of the reference series was calcu-
lated by dividing the number of reads for each ampli-
con by the total number of reads for each normal
tissue sample. The arithmetic mean was calculated for
each amplicon, based on all samples in the reference
series. The coverage of each amplicon from the
tumour tissue samples was normalized by dividing the
number of reads by the total number of reads per
tumour tissue sample. The relative coverage for each
amplicon of the tumour tissue samples was calculated
by dividing the normalized coverage of the sample by
the mean normalized coverage of the reference series
(Eijkelenboom et al., 2019). Copy number gains were
suspected when at least five amplicons clustered
together, provided that the log2 scale of the relative
coverage amounted > 1.5. Copy number losses were
not investigated as the presence of background (due to
the use of FFPE tissue samples) hampered reliable
interpretation of the presence of copy number losses.
Visualization of CNVs was achieved by the construc-




Ten patients with a breast cancer with spatially hetero-
geneous HER2 amplification were included in this
study. This series included eight patients with invasive
carcinoma of no special type (NST) and associated
ductal carcinoma in situ (DCIS), one patient with
invasive lobular carcinoma (ILC) and associated lobu-
lar carcinoma in situ (LCIS), and one patient with
metaplastic carcinoma (MC; spindle cell type) and
associated DCIS. Figure 1 illustrates the presence of a
HER2-positive and a HER2-negative DCIS compo-
nent, associated with a HER2-positive invasive MC
(patient #1). Figure 2 demonstrates the presence of a
HER2-positive and HER2-negative LCIS component
associated with a HER2-negative invasive component
(patient #3). In some patients, heterogeneous HER2
amplification was associated with heterogeneous hor-
mone receptor status as well (Fig. S1; Table 1). All
patients underwent nodal staging. Six patients had no
sentinel lymph node metastases. Patient #10 had seven
axillary macrometastases, with sufficient tissue avail-
able for targeted NGS. Patients #4, #9 and #5 had a
sentinel lymph node with isolated tumour cells, a sin-
gle micrometastasis and a single macrometastasis,
respectively. These metastases were not analysed due
to insufficient amounts of available tumour tissue.
Fig. 1. Heterogeneous CNVs and heterogeneous HER2 and EGFR expression in the tumour of patient #1. The scatter plot illustrates the
presence of a HER2 copy number gain in one DCIS component and in the MC, as well as an EGFR copy number gain in the HER2-negative
DCIS component (A). Immunohistochemistry for HER2, with an overview of breast cancer #1 (B; original magnification 12.59 – scale bar
size = 2.5 mm), and detailed microphotographs of the HER2-positive DCIS (C), the HER2-positive MC (D) and the HER2-negative DCIS (E;
original magnification 1009 – scale bar size = 250 µm). Immunohistochemistry for EGFR, which was positive in the HER2-negative DCIS
component (F) and negative in the HER2-positive DCIS (G) and in the HER2-positive MC (H; original magnification 1009 – scale bar size
300 µm).
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3.2. Coverage and mutation analysis
Sufficient DNA for sequencing was extracted from all
but two microdissected tissue samples (Table 1). The
mean percentage of amplicons with at least 100 and
500 reads was 94.4% and 78.5%, respectively, with an
average base coverage depth of 2216 (Table S3). No
pathogenic or likely pathogenic somatic variants were
detected in ARID1B, BRCA2, CCND3, CHECK2,
ERBB2, ERBB3, MAP2K4, MLL, NCOR1, NOTCH1,
PBRM1 and PDGFRA. Overall, germline pathogenic
variants were not observed.
We identified 63 pathogenic or probably pathogenic
variants in 26 different genes (Table S4), based on four
prediction tools and the COSMIC database. These
variants included 12 deletions, 9 insertions, 32
missense variants, 7 nonsense variants (with introduc-
tion of a stop codon) and 3 splice site alterations.
These somatic aberrations were commonly found in
ARID1A, MLL3, NF1, PIK3CA and TP53 (Fig. 3).
The tumour suppressor gene TP53 was mutated in at
least one component in 7 out of 10 breast cancers
(70%). The TP53 aberrations included five missense
variants, two deletions and one splice site change. The
presence of a TP53 mutation was homogeneously pre-
sent in all components of the breast cancers of patients
#4, #5 and #8. Patients #1, #2, #7 and #10 each pre-
sented with a tumour with heterogeneous presence of a
TP53 mutation (Table 2). Patient #1 presented a
p.R248W TP53 mutation in the HER2-negative DCIS
component and the HER2-positive invasive compo-
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Fig. 2. Heterogeneous HER2 overexpression and CNVs in the breast cancer of patient #3. Immunohistochemistry for E-cadherin (A)
illustrates the absence of expression in all tumour components (original magnification 509 – scale bar size = 500 µm).
Immunohistochemistry for HER2 (B) demonstrates a positive 3+ score in the HER2-amplified LCIS component (orange squares) and an
equivocal 2+ score in the HER2 nonamplified LCIS component (blue diamond) and the ILC of classic type (grey triangle; original
magnification 50x – scale bar size = 500 µm). The scatter plot confirms the HER2 copy number gain in the HER2-positive LCIS (indicated by
orange squares) and its absence in the HER2-negative components (C). Additionally, the presence of an FGFR1 copy number gain in the ILC
is noted (indicated by grey triangles).
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component. However, the latter presented with a
p.Y234H TP53 mutation. Patient #2 presented with a
p.S241fs deletion in both the HER2-positive DCIS
and the HER2-positive invasive component, whereas
the HER2-negative DCIS component harboured a
p.R273C missense variant. Patient #7 showed a
p.R209fs TP53 deletion in the HER2-positive DCIS
component, which was not detected in the associated
HER2-negative invasive component. Patient #10
showed a p.D259V missense variant in the HER2-neg-
ative invasive component, which was not detected in
the HER2-positive DCIS, nor in the HER2-negative
axillary metastasis.
Seven out of ten (70%) breast cancers harboured a
PIK3CA mutation in at least one tumour component.
Patients #1, #4, #5, #7 and #9 presented with a breast
cancer with homogeneous presence of a PIK3CA
mutation in each individual tumour component,
whereas PIK3CA mutations were heterogeneously
distributed in the tumours of patients #3 and #6
(Table 2). Patient #3 showed a p.G1049R missense
mutation in the HER2-negative invasive component,
which was not detected in the DCIS components, irre-
spective of their HER2 status. Patient #6 showed a
p.Q546E PIK3CA mutation which was present in the
HER2-negative invasive component and absent in the
admixed HER2-positive invasive component. Patient
#4 had a p.H1047R PIK3CA mutation in each tumour
component, but the HER2-negative invasive compo-
nent harboured an additional p.W1057X mutation,
which was not detected in the other tumour compo-
nents. Somatic ARID1A, MLL3 and NF1 mutations
were found in at least one component in three, six and
four breast tumours, respectively, and the presence of
these mutations was unrelated to the HER2 status
(Fig. S2, Table 2). For instance, patient #1 showed a
p.C327F MLL3 mutation in the HER2-positive carci-
noma component, which was absent in both DCIS
Table 1. Detailed patient and tumour characteristics. Hormone receptor status and HER2 receptor status are indicated for each in situ and
invasive tumour component. ER+, oestrogen receptor-positive; ER, oestrogen receptor-negative; ID, patient pseudonym; NAC,
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10 42 3 19 pT1c
N2b








aAs measured in the resection specimen.
bMiller–Payne response grade 3
cSingle duct, which disappeared during tissue sectioning; not included in this study because of insufficient material for targeted sequencing.
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components. Patient #3 had a nonsense mutation in
the HER2-negative invasive component, which was
lacking in both DCIS components. Patient #8 had a
missense MLL3 mutation in the HER2-positive DCIS
and HER2-negative invasive component, whereas the
HER2-negative DCIS component presented with a dif-
ferent nonsense MLL3 mutation.
Less common somatic variants were observed in
AKAP9, ATM, BRCA1, CBFB, CDH1, EGFR, ESR1,
FBXW7, GATA3, MAP3K1, MED12, MLL2, MLLT4,
NFATC2, PTEN, RB1, RNF213, RUNX1, SF3B1,
SPEN and TBX3 (Table S5). Somatic mutations in
these genes were often heterogeneously present
throughout the different tumour components, and
their presence seemed unrelated to the HER2 amplifi-
cation status, except for GATA3 mutations. Somatic
GATA3 mutations occurred in HER2-positive tumour
components. Patient #2 had a GATA3 mutation in the
HER2-positive in situ and invasive components, which
was absent in the HER2-negative invasive carcinoma
component. Patient #3 had a GATA3 splice site muta-
tion in the HER2-positive LCIS component, which



























Missense Deleon Splice site mutaon
Nonsense Inseron
Fig. 3. Overview of detected pathogenic and likely pathogenic variants in 26 genes per patient. Green and blue squares indicate missense
and nonsense mutations, respectively. Red and orange squares indicate deletions and insertions, respectively. Splice site mutations are
indicated by purple squares.
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was not observed in the HER2-negative in situ and
invasive components.
3.3. Copy number variation analysis
The presence of high-level CNVs was investigated, and
confirmed the presence of HER2 amplification in all
HER2-positive carcinoma samples, which served as an
internal quality control (Figs 1 and 2; Figs S1 and S2).
Additionally, we observed an EGFR copy number gain
in the HER2-negative DCIS component of patient #1
(Fig. 1). Patients #3 and #5 had an FGFR1 copy num-
ber gain in at least one tumour component. In patient
#3, the HER2-negative ILC harboured this FGFR1
amplification (Fig. 2), which was absent in the HER2-
negative and HER2-positive LCIS components. In
patient #5, all tumour components displayed the
FGFR1 copy number gain. Patients #9 and #10 both
had a HER2-negative tumour component with a gain
of 8q24, which comprised a copy number gain of both
MYC and the adjacent long noncoding RNA
(lncRNA) plasmacytoma variant translocation 1
(PVT1). Patient #9 also had a CCND1 copy number
gain in the HER2-negative tumour component. The
potential presence of copy number losses was difficult
to interpret with certainty, as some amplicons showed
a consistently lower coverage throughout this series.
The use of FFPE samples caused a relatively high
background, which further hampered the assessment
of any potentially relevant deletions.
3.4. Complementary immunohistochemical
analysis
Immunohistochemistry for EGFR was performed on
all tumour tissue samples. In patient #1, the identified
EGFR amplification in the HER2-negative DCIS com-
ponent was associated with EGFR protein overexpres-
sion (Fig. 1F–H). No EGFR protein overexpression
was noted in the other tumours (data not shown).
Immunohistochemistry for FGFR1 was performed on
tumour tissue samples of patients #3 and #5, which
revealed no apparent positivity in either of the tumour
components (data not shown).
4. Discussion
Carcinogenesis is an evolutionary process governed by
the principles of Darwinian dynamics (Gillies et al.,
2012). Tumours are clonal proliferations, originating
from a single cell that acquired genomic instability
through an accumulation of somatic mutations. Early
genomic anomalies, including crucial oncogenic
drivers, will therefore be present in all tumour cells
and constitute clonal molecular aberrations. Acquisi-
tion of additional oncogenic drivers and passenger
mutations will result in subpopulations of cancer cells
with different genotypes and phenotypes, and these
subclonal aberrations contribute to intratumour
heterogeneity (McDonald et al., 2019). This hetero-
geneity is caused by somatic mutations and CNVs, as
well as differences in epigenetics (Assenov et al., 2018;
Easwaran et al., 2014). Somatic evolution is driven by
a combination of genetic instability and a selective
tumour microenvironment, including acidosis, hypoxia
and cytotoxic stress imposed by chemotherapy, hor-
monal therapy and/or targeted therapies (Gillies et al.,
2012). HER2-targeted therapies impose an evolution-
ary selection pressure on HER2-positive cancer cells.
Those cancer cell populations that are not exclusively
dependent on the overexpression of the HER2 onco-
gene will be able to constitute an anti-HER2 therapy-
resistant subclone, regardless of their HER2 status.
These subclones harbour alternative and/or collabora-
tive drivers of carcinogenesis, which circumvent the
blockade of the HER2-driven pathways. The high
prevalence of both intrinsic and acquired resistance to
single-agent treatment regimens already caused a shift
towards dual HER2-targeted therapy, such as per-
tuzumab or T-DM1 (Konecny, 2013; Pernas et al.,
2018).
Interestingly, 5–41% of HER2-positive breast can-
cers present with regional heterogeneous HER2 ampli-
fication (Cottu et al., 2008; Ng et al., 2015), although
this percentage depends on the applied definition. In
this study, we subjected ten breast cancers with spa-
tially heterogeneous HER2 amplification and corre-
sponding HER2 overexpression to targeted NGS. We
investigated the potential heterogeneity in the somatic
mutational landscape of each individual tumour com-
ponent. Some mutations were, if present, homoge-
neously found in each component. For instance, four
of seven tumours with a PIK3CA mutation presented
this mutation in each component. Somatic TP53 muta-
tions seemed more often heterogeneously distributed,
and their presence seemed generally unrelated to the
HER2 amplification status.
Two breast cancers in this series harboured a gain
of the 8q24 region, comprising both MYC and the
adjacent lncRNA PVT1, which stabilizes the MYC
protein and enhances its activity (Tseng and Bagchi,
2015). Co-amplified MYC and PVT1 genes have been
identified as candidate oncogenes in ER-positive,
HER2-positive breast cancers (Sircoulomb et al.,
2010). A recent meta-analysis concluded that increased
PVT1 expression was associated with lower overall
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survival in a wide variety of solid tumours, including
breast cancer (Zou et al., 2019). High PVT1 expression
was associated with clinicopathological markers of
poor prognosis, such as larger tumour size, higher
TNM stage and the presence of both lymph node and
distant metastases (Zou et al., 2019). In vitro studies
demonstrated that PVT1 expression drives cancer cell
proliferation through promotion of the KLF5/BAP1/
beta-catenin signalling pathway (Tang et al., 2018).
One patient had a CCND1 copy number gain in a
HER2-negative invasive tumour component. CCND1
amplification is associated with a particular gene
expression profile and decreased survival in ER-posi-
tive, HER2-negative node-negative breast cancer
patients (Lundberg et al., 2019), indicating that
CCND1 amplification might act as an alternative dri-
ver of carcinogenesis. Similar observations have been
reported for FGFR1 amplification within breast cancer
and other types of carcinoma (Helsten et al., 2016).
By using targeted NGS with a 53-gene panel, we
identified a plethora of somatic mutations and CNVs
within the HER2-negative components in this series of
ten HER2 heterogeneous breast cancers. The genetic
heterogeneity within both the HER2-negative and
HER2-positive components of a single tumour sug-
gests that a wide range of different somatic mutations
and/or CNVs may act as potential alternative drivers.
These genetic aberrations might counterbalance the
absence of HER2 amplification in the HER2-negative
components. Of note, this targeted NGS-driven study
focussed only on a subset of 53 breast cancer-related
genes in a limited series of ten breast cancer patients.
Since we did not apply whole-genome sequencing on a
large patient series, it is impossible to exclude the exis-
tence of a more commonly present alternative driver in
HER2-negative tumour components. Due to the use of
FFPE material, we were confronted with high levels of
background in some tumour tissue samples, which pre-
cluded an in-depth analysis of potentially important
copy number losses. Nevertheless, our findings are in
accordance with the observations of the TCGA net-
work, who described a high frequency of TP53 (55%)
and PIK3CA (31%) mutations, and an low frequency
of mutations in RUNX1 (1%), PTEN (0%), NCOR
(0%) and CDH1 (3%) in 75 clinically HER2-positive
breast cancers (Koboldt et al., 2012). The TCGA net-
work identified a high frequency of TP53 mutations in
ER-negative, HER2-positive breast cancers, whereas
ER-positive, HER2-positive breast cancers displayed
more often a GATA3 mutation (Koboldt et al., 2012).
This hormone receptor-dependent duality was not
observed in our series, which might be due to its small
size.
The limited gene panel precludes strong statements
regarding the clonal relationship of all components
within a single tumour. However, the integration of
histopathological and immunohistochemical features,
together with the uniform presence of some well-de-
fined pathogenic mutations (such as TP53 or PIK3CA
mutations), suggests a common progenitor for most
heterogeneous lesions in this series. Based on the fre-
quent homogeneous presence of the observed variants,
it was estimated that the tumours of patients #1, #3,
#4, #5, #7 and #9 were likely to have a common pro-
genitor. The tumours of patients #2, #6 and #10 were
considered to be less likely related to one another (i.e.,
a collision tumour of two independent neoplastic
lesions), or to have a common progenitor with very
early divergence of the subclones. Despite its limited
size, this series of ten breast cancers demonstrates that
regional heterogeneity in HER2 status is associated
with further heterogeneity at the molecular level, and
sometimes also at the protein level, since some tumour
components presented with different hormone receptor
status and/or EGFR protein expression status.
Although regional HER2 heterogeneity is uncommon,
this series illustrates that not all cells within one
tumour depend exclusively on HER2 amplification and
overexpression.
Due to its relatively high prevalence in invasive
breast cancer and its association with worse prognosis,
HER2 overexpression is suspected to play a major role
as a driver of mammary carcinogenesis. HER2-positive
invasive breast cancer more often presents with an
associated in situ component, and if present, this DCIS
component is substantially larger than in HER2-nega-
tive tumours (Doebar et al., 2016). The prevalence of
HER2 overexpression amounts 35% in pure DCIS,
which is paradoxically higher than its prevalence in
invasive breast cancer (Siziopikou et al., 2013). Over-
all, HER2 expression profiles are highly concordant
between admixed in situ and invasive breast cancer,
but overexpression/amplification is less common in the
DCIS component of admixed lesions than in pure
DCIS (Burkhardt et al., 2010; Lambein et al., 2017;
Latta et al., 2002; Park et al., 2006). One in three
women with a HER2-positive pure DCIS lesion devel-
ops a subsequent HER2-negative invasive breast can-
cer (Visser et al., 2019), although the clonal
relationship between primary and recurrent lesions was
not investigated in that study. Taken together, these
observations indicate that HER2 overexpression is
more likely to play a role as an instigator of tumour
cell proliferation, rather than being a crucial driver of
cancer cell invasion (Sanati, 2019). The series of patho-
genic and likely pathogenic somatic variants that we
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describe here yields a wide range of potential alterna-
tive drivers of cancer cell proliferation and invasion.
Moreover, some genetic anomalies (such as PIK3CA
and GATA3 mutations, or FGFR1 copy number gain)
might drive resistance to treatment (Pernas et al.,
2018; Turner et al., 2010).
5. Conclusion
The HER2-negative components of HER2 heteroge-
neous breast cancers display a variety of somatic
mutations and CNVs within 53 breast cancer-related
genes. Although these somatic mutations and CNVs
were often present in the HER2-positive component as
well, they might act as potential alternative drivers to
counterbalance the absence of HER2 amplification.
Since these potential alternative drivers may have the
capacity to circumvent HER2 pathway blockade, their
widespread presence throughout these HER2 heteroge-
neous cancers might explain the high level of innate
and acquired resistance to HER2-targeted therapies in
breast cancer. Our findings indirectly imply that a tar-
geted monotherapy is unlikely to have high efficacy in
the long term, since it causes cytotoxic distress and
selection of those resistant clones that already harbour
alternative drivers of carcinogenesis. Future transla-
tional breast cancer research should focus on how to
handle this molecular heterogeneity in the clinical set-
ting.
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Fig. S1. Copy number variations, HER2 status and
hormone receptor status in the breast cancer of patient
#6. The scatter plot confirms the presence of a HER2
copy number gain in the HER2-positive invasive carci-
noma component (A; indicated by red squares).
Immunohistochemistry for HER2 (B), oestrogen recep-
tor (C) and progesterone receptor (D) illustrate oppo-
site protein expression profiles in both invasive
carcinoma components (original magnification 12,5x –
scale bar size = 2,5 mm).
Fig. S2. Copy number variations in the breast cancers
of patients #5, #9 and #10. The scatter plot of
patient #5 (A) confirms a HER2 copy number gain
in the HER2-positive invasive carcinoma component
(indicated by green triangles), and demonstrates an
FGFR1 copy number gain (cytogenetic location:
8p11.23) in each tumour component. The tumour of
patient #9 harbours a neighbouring copy number
gain located at 8q24 in all carcinoma components,
which comprises both the MYC and PVT1 genes, as
well as a CCND1 copy number gain in the HER2-
negative invasive carcinoma component (B). A similar
8q24 copy number gain was noted in the HER2-nega-
tive invasive carcinoma component (indicated by red
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triangles) of patient #10 (C). In patient #9, this co-
amplification was present in both the HER2-positive
DCIS and the HER2-negative invasive carcinoma
components, indicating that this genetic aberration
can occur as an early event in carcinogenesis. How-
ever, this co-amplification was not present in the
HER2-positive DCIS component and the HER2-neg-
ative axillary metastasis.
Table S1. Materials and methods for immunohisto-
chemistry.
Table S2. List of genes included in the panel used for
targeted next-generation sequencing.
Table S3. Detailed information on base coverage and
number of reads for targeted next-generation sequenc-
ing of normal and tumour tissue samples of ten breast
cancers with regional HER2 heterogeneity.
Table S4. Mutation analysis.
Table S5. Detailed information on the presence of
somatic mutations in the less frequently mutated genes
per patient and per tumour component.
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